In summary, the results of this study extend the picture of adverse clinical outcome associated with TP53 mutations in ALK+ NSCLC, and demonstrate the great potential of ctDNA assays for molecular profiling and longitudinal monitoring in ALK+ NSCLC beyond detection of ALK resistance mutations. Here, TP53 is linked to non-small cell lung carcinoma.